In key win, Ab­b­Vie lands FDA ap­proval for Al­ler­gan's blurred-vi­sion eye drop

Ab­b­Vie’s age-re­lat­ed blur­ry vi­sion drug for ag­ing adults was giv­en the OK by the FDA Fri­day, mak­ing it the first eye drop to treat an eye con­di­tion that af­fects 128 mil­lion Amer­i­cans.

For­mer­ly AGN-190584, the drug has proven a bright spot in Al­ler­gan’s pipeline since Ab­b­Vie bought it out for $63 bil­lion, which has seen more set­backs than wins.

The dai­ly pre­scrip­tion eye drop is ap­proved to treat pres­by­opia. Vuity is a for­mu­la­tion of pi­lo­carpine, a well-known drug for in­traoc­u­lar pres­sure and var­i­ous types of glau­co­ma, among oth­er us­es. Al­ler­gan had de­ployed a dif­fer­ent de­liv­ery method that promised to make the drug bet­ter tol­er­at­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.